



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/595,444	02/23/2007	Keith Biggadike	PB60557	9783
23347	7590	11/16/2009	EXAMINER	
GLAXOSMITHKLINE			OH, TAYLOR V	
CORPORATE INTELLECTUAL PROPERTY, MAI B482			ART UNIT	PAPER NUMBER
FIVE MOORE DR., PO BOX 13398			1625	
RESEARCH TRIANGLE PARK, NC 27709-3398				
NOTIFICATION DATE		DELIVERY MODE		
11/16/2009		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USCIPRTP@GSK.COM
LAURA.M.MCCULLEN@GSK.COM
JULIE.D.MCFALLS@GSK.COM

Office Action Summary	Application No.	Applicant(s)	
	10/595,444	BIGGADIKE, KEITH	
	Examiner	Art Unit	
	Taylor Victor Oh	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 20 April 2006.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-10, 13 and 15-21 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-10, 13, 15-21 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____ .	6) <input type="checkbox"/> Other: _____ .


LACK OF UNITY

Restriction is required under 35 U.S.C. 121 and 372.


This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-9,13,15-18, drawn to a compound of formula I:




or a salt, solvate, or physiologically functional derivative thereof, wherein:




Ar^1 is a group selected from

(a)

Group II, claims 1-7,13,15-18, drawn to a compound of formula I:




or a salt, solvate, or physiologically functional derivative thereof, wherein:




Ar^1 is a group selected from (b)

Group III, claims 1-6, 13,15-18, drawn to a compound of formula I :




or a salt, solvate, or physiologically functional derivative thereof, wherein:



Ar¹ is a group selected from

(c)


Group IV, claims 1-6, 13,15-18, drawn to a compound of formula I :



(I)

or a salt, solvate, or physiologically functional derivative thereof, wherein:

Ar¹ is a group selected from



(d)

Group V, claims 10 and 19-21, drawn to a method for the prophylaxis or treatment of a clinical conditions in a mammal, such as asthma or COPD using the formula (I).

The inventions listed as Groups I -V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

The international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (" requirement of unity of invention ").

PCT Rule 13.2 states " Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression " special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

In the instant case , the invention of Group I is directed to the compound of formula I with phenyl group, whereas the invention of Group II is directed to the compound of formula I with pyridinyl group The heteroaryl group is attached to the main core structure. They have different modes of operation , different functions or different effects with respect to each other because each linker has a completely different

chemical structure with respect to the core structure. For example, the reactant containing the pyridinyl group has been known to have a different reactivity or a different effect in comparison with the one with the phenyl group. Therefore, Group I and Group II are unrelated to each other. In addition, each invention has a different use and effect due to the unrelated substituent attached to the core of the compounds. Therefore, there is no single general inventive concept and no unity of invention for the method or the process as defined in 37 CFR 1.475.

From this, the Group I is not required for the invention of Group II. Therefore, there is no special technical feature between Group I and Group II.

In the instant case , the invention of Group I is directed to the compound of formula I with phenyl group, whereas the invention of Group III is directed to the compound of formula I with oxazole group The heteroaryl group is attached to the main core structure. They have different modes of operation , different functions or different effects with respect to each other because each linker has a completely different chemical structure with respect to the core structure. For example, the reactant containing the oxazole group has been known to have a different reactivity or a different effect in comparison with the one with the phenyl group. Therefore, Group I and Group II are unrelated to each other. In addition, each invention has a different use and effect due to the unrelated substituent attached to the core of the compounds. Therefore, there is no single general inventive concept and no unity of invention for the method or the process as defined in 37 CFR 1.475.

From this, the Group I is not required for the invention of Group II. Therefore, there is no special technical feature between Group I and Group III.

In the instant case, the invention of Group I is directed to the compound of formula I with phenyl group, whereas the invention of Group IV is directed to the compound of formula I with pyran group. The heteroaryl group is attached to the main core structure. They have different modes of operation, different functions or different effects with respect to each other because each linker has a completely different chemical structure with respect to the core structure. For example, the reactant containing the pyran group has been known to have a different reactivity or a different effect in comparison with the one with the phenyl group. Therefore, Group I and Group II are unrelated to each other. In addition, each invention has a different use and effect due to the unrelated substituent attached to the core of the compounds. Therefore, there is no single general inventive concept and no unity of invention for the method or the process as defined in 37 CFR 1.475.

From this, the Group I is not required for the invention of Group IV. Therefore, there is no special technical feature between Group I and Group IV.

In the instant case, the invention of Group I is directed to the compound having Ar^1 equal to the phenyl group according to formula (I), whereas the invention of Group V is directed to method for the prophylaxis or treatment of a clinical conditions in a mammal, such as asthma or COPD using the formula (I).

According to Jerussi (U.S. 6,294,582), the reference discloses the method for treating asthma or COPD using an s-oxybutynin. From this, the Group V is not required for the invention of Group I. Therefore, there is no special technical feature between Group I and Group V.

Therefore, there is no single general inventive concept and no unity of invention for the method or the compounds as defined in 37 CFR 1.475.

Therefore, there is no single general inventive concept and no unity of invention for the method or the process as defined in 37 CFR 1.475.

37 CFR 1.475 states that a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combination of categories:

- a. A product and a process specially adapted for the manufacture of said product; or
- b. A product and a process of use of said product; or
- c. A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- d. A process and an apparatus or means specially designed for carrying out the said process; or
- e. A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specially designed for carrying out the said process.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taylor Victor Oh whose telephone number is 571-272-0689. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Taylor Victor Oh/
Primary Examiner, Art Unit 1625
11/09/09